Pyxis Oncology reported a net loss of $20.0 million, or ($0.24) per share, for the quarter ended September 30, 2026, compared to a $22.0 million loss in the prior-year period. Research and development expenses decreased to $16.6 million from $17.8 million, while general and administrative expenses fell to $4.0 million from $5.7 million. The company holds approximately $57.0 million in cash and investments as of quarter-end, supplemented by net proceeds from a recent public offering that generated roughly $110.0 million in upfront gross proceeds. Pyxis Oncology is a clinical-stage biopharmaceutical company developing next-generation therapeutics for difficult-to-treat cancers.
